Last SFr.16.70 CHF
Change Today +0.20 / 1.21%
Volume 14.2K
NWRN On Other Exchanges
SIX Swiss Ex
As of 9:04 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

newron pharmaceuticals spa (NWRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/18/13 - SFr.19.50
52 Week Low
09/25/13 - SFr.8.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

newron pharmaceuticals spa (NWRN) Related Businessweek News

No Related Businessweek News Found

newron pharmaceuticals spa (NWRN) Details

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain. Its lead product is safinamide that has completed Phase III trials for the treatment of patients with Parkinson’s disease. The company also has a pipeline of novel drug candidates in Phase II trials, which include sNN0031 for the treatment of Parkinson’s disease patients, sNN0029 for the treatment of amyotrophic lateral sclerosis, and Sarizotan for the treatment of Rett’s syndrome. In addition, it develops NW-3509 that is in Phase I trials for the treatment of schizophrenia; and ralfinamide, which is in Phase II trials for the treatment of neuropathic pain. It has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development of safinamide in Japan and Asia. Newron Pharmaceuticals S.p.A. was founded in 1998 and is headquartered in Bresso, Italy.

23 Employees
Last Reported Date: 03/4/14
Founded in 1998

newron pharmaceuticals spa (NWRN) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €390.0K
Chief Medical Officer
Total Annual Compensation: €752.0K
Compensation as of Fiscal Year 2013.

newron pharmaceuticals spa (NWRN) Key Developments

Newron Pharmaceuticals S.p.A Announces Earnings Results for the First Half of 2014

Newron Pharmaceuticals S.p.A. announced earnings results for the first half of 2014. For the first half, the company reported that it has invested EUR 6.5 million into drug development and preparations for regulatory submission of safinamide, up from EUR 4.4 million in 2013. Revenues for the first half of 2014 were EUR 1.4 million, stemming from recognition of a 2012 license down-payment over the period of collaboration with partner Zambon, as well as the US submission milestone. The net loss amounted to EUR 4.6 million, compared to EUR 2.4 million in 2013. Loss per share was EUR 0.37 against EUR 0.21, a year ago. Net cash used in operating activities was EUR 4,443,000 against EUR 7,299,000 a year go.

Newron Pharmaceuticals S.p.A. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

Newron Pharmaceuticals S.p.A. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

Newron Pharmaceuticals S.p.A. and Zambon Company S.p.A. Announces Safinamide New Drug Application Submitted to the US Food and Drug Administration

Newron Pharmaceuticals S.p.A. and its partner Zambon S.p.A. announced that the New Drug Application for safinamide was submitted to the US Food and Drug Administration. The submission covers the indications "safinamide as add-on therapy to a stable dose of a single dopamine agonist" in early Parkinson's disease patients and "safinamide as add-on therapy to levodopa alone or in combination with other Parkinson's disease treatments" in mid-to late stage Parkinson's disease patients. The submission was based on completion of activities agreed upon during meetings with the FDA. The submission was made by Newron, which is the NDA holder until completion of the sublicense process for the US rights to safinamide, by Zambon.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWRN:SW SFr.16.70 CHF +0.20

NWRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWRN.
View Industry Companies

Industry Analysis


Industry Average

Valuation NWRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.9x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWRON PHARMACEUTICALS SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at